MRNA Moderna Inc Coronavirus vaccine: 30,000 participant Phase 3 study expected to begin on July 27

2020-Jul-22 at 12:16 am

Moderna has completed manufacture of vaccine required to start the Phase 3 study. With the Phase 3 dose being finalized at 100 µg, the Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the Company’s internal U.S. manufacturing site and strategic collaboration with Lonza.